Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity

B G J Dekkers; O W Akkerman; J W C Alffenaar

doi:10.1128/AAC.02074-18

Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity

Antimicrob Agents Chemother. 2019 Jan 29;63(2):e02074-18. doi: 10.1128/AAC.02074-18. Print 2019 Feb.

Authors

B G J Dekkers¹, O W Akkerman^{2

3}, J W C Alffenaar⁴

Affiliations

¹ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
² University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
³ University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
⁴ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands [email protected].

No abstract available

Keywords: azithromycin; diabetes mellitus; ethambutol; moxifloxacin; pharmacokinetics; pyrazinamide; rifampin; therapeutic drug monitoring; tuberculosis.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Comorbidity
Diabetes Mellitus*
Drug Monitoring
Humans
Pyrazinamide
Tuberculosis*

Substances

Pyrazinamide